123 related articles for article (PubMed ID: 10919640)
1. Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53.
Shiraishi K; Fukuda S; Mori T; Matsuda K; Yamaguchi T; Tanikawa C; Ogawa M; Nakamura Y; Arakawa H
Cancer Res; 2000 Jul; 60(14):3722-6. PubMed ID: 10919640
[TBL] [Abstract][Full Text] [Related]
2. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53.
Mori T; Anazawa Y; Iiizumi M; Fukuda S; Nakamura Y; Arakawa H
Oncogene; 2002 Apr; 21(18):2914-8. PubMed ID: 11973653
[TBL] [Abstract][Full Text] [Related]
3. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.
Mirza A; McGuirk M; Hockenberry TN; Wu Q; Ashar H; Black S; Wen SF; Wang L; Kirschmeier P; Bishop WR; Nielsen LL; Pickett CB; Liu S
Oncogene; 2002 Apr; 21(17):2613-22. PubMed ID: 11965534
[TBL] [Abstract][Full Text] [Related]
4. Transcription factors Oct-1 and NF-YA regulate the p53-independent induction of the GADD45 following DNA damage.
Jin S; Fan F; Fan W; Zhao H; Tong T; Blanck P; Alomo I; Rajasekaran B; Zhan Q
Oncogene; 2001 May; 20(21):2683-90. PubMed ID: 11420680
[TBL] [Abstract][Full Text] [Related]
5. Expression of CX3C chemokine, fractalkine, and its receptor CX3CR1 in experimental autoimmune anterior uveitis.
Fang IM; Lin CP; Yang CM; Chen MS; Yang CH
Mol Vis; 2005 Jul; 11():443-51. PubMed ID: 16030495
[TBL] [Abstract][Full Text] [Related]
6. Fractalkine shares signal sequence with TARC: gene structures and expression profiles of two chemokine genes.
Hiroyama T; Iwama A; Nakamura Y; Nakauchi H
Genomics; 2001 Jul; 75(1-3):3-5. PubMed ID: 11472060
[TBL] [Abstract][Full Text] [Related]
7. Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis.
Blaschke S; Koziolek M; Schwarz A; Benöhr P; Middel P; Schwarz G; Hummel KM; Müller GA
J Rheumatol; 2003 Sep; 30(9):1918-27. PubMed ID: 12966591
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells.
Xu D; Wang Q; Gruber A; Björkholm M; Chen Z; Zaid A; Selivanova G; Peterson C; Wiman KG; Pisa P
Oncogene; 2000 Oct; 19(45):5123-33. PubMed ID: 11064449
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional regulation of the mouse PNRC2 promoter by the nuclear factor Y (NFY) and E2F1.
Zhou D; Masri S; Ye JJ; Chen S
Gene; 2005 Nov; 361():89-100. PubMed ID: 16181749
[TBL] [Abstract][Full Text] [Related]
10. Gene cloning, RNA distribution, and functional expression of mCX3CR1, a mouse chemotactic receptor for the CX3C chemokine fractalkine.
Combadiere C; Gao J; Tiffany HL; Murphy PM
Biochem Biophys Res Commun; 1998 Dec; 253(3):728-32. PubMed ID: 9918795
[TBL] [Abstract][Full Text] [Related]
11. The effect of Toxoplasma gondii infection on expression of chemokines by rat retinal vascular endothelial cells.
Knight BC; Brunton CL; Modi NC; Wallace GR; Stanford MR
J Neuroimmunol; 2005 Mar; 160(1-2):41-7. PubMed ID: 15710456
[TBL] [Abstract][Full Text] [Related]
12. Introduction of p16INK4a inhibits telomerase activity through transcriptional suppression of human telomerase reverse transcriptase expression in human gliomas.
Saito M; Nakagawa K; Hamada K; Hirose S; Harada H; Kohno S; Nagato S; Ohnishi T
Int J Oncol; 2004 May; 24(5):1213-20. PubMed ID: 15067344
[TBL] [Abstract][Full Text] [Related]
13. The neurogene BTG2TIS21/PC3 is transactivated by DeltaNp73alpha via p53 specifically in neuroblastoma cells.
Goldschneider D; Million K; Meiller A; Haddada H; Puisieux A; Bénard J; May E; Douc-Rasy S
J Cell Sci; 2005 Mar; 118(Pt 6):1245-53. PubMed ID: 15741235
[TBL] [Abstract][Full Text] [Related]
14. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients.
Ohta M; Tanaka F; Yamaguchi H; Sadanaga N; Inoue H; Mori M
Int J Oncol; 2005 Jan; 26(1):41-7. PubMed ID: 15586223
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
[TBL] [Abstract][Full Text] [Related]
16. Characterization of promoter elements involved in the down-regulation of topoisomerase IIalpha expression in a drug-resistant cell line.
Saxena D; Yiu GK; Ni X; Huang KC; Mantovani R; Jacquemin-Sablon AG; Ng SW
Gene; 2004 Nov; 342(1):145-55. PubMed ID: 15527974
[TBL] [Abstract][Full Text] [Related]
17. Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1.
Britschgi C; Rizzi M; Grob TJ; Tschan MP; Hügli B; Reddy VA; Andres AC; Torbett BE; Tobler A; Fey MF
Oncogene; 2006 Mar; 25(14):2030-9. PubMed ID: 16301995
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis.
Huang Y; Tan M; Gosink M; Wang KK; Sun Y
Cancer Res; 2002 May; 62(10):2913-22. PubMed ID: 12019172
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the Oct-1 regulatory element of the gadd45 promoter in the p53-independent response to ultraviolet irradiation.
Takahashi S; Saito S; Ohtani N; Sakai T
Cancer Res; 2001 Feb; 61(3):1187-95. PubMed ID: 11221850
[TBL] [Abstract][Full Text] [Related]
20. p53 upregulates death receptor 4 expression through an intronic p53 binding site.
Liu X; Yue P; Khuri FR; Sun SY
Cancer Res; 2004 Aug; 64(15):5078-83. PubMed ID: 15289308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
